Compare Adaptive Biotechnologies Corp (ADPT) vs Infosys Limited (INFY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Infosys Limited — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while Infosys Limited trades at $11.02 (market cap $46.00B). The key difference: Infosys Limited is far larger — about 13.8× Adaptive Biotechnologies Corp's market cap, and Infosys Limited pays a 4.65% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | INFY | |
|---|---|---|
Market Cap | $3.33B | $46.00B |
Sector | Health | Technology |
52-Week High | $22.37 | $20.22 |
52-Week Low | $10.24 | $10.49 |
Enterprise Value | $3.19B | $43.21B |
Dividend Yield | — | 4.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
INFY trades at $10.88, down 2.51% on the day, with a bearish technical signal from moving averages. The company reported strong profitability with a net income margin of 16.44% and ROE of 31.57% for 2025, while recent earnings have mostly beaten expectations. Analyst consensus is a 'Hold' with a $13.18 price target, suggesting potential upside. Recent news highlights multiple AI collaborations, such as with Sentara and GlobalFoundries, indicating strategic focus on AI-driven growth.
The outlook for INFY is mixed; fundamentals remain solid with steady revenue growth and high profitability, but technical indicators and sector-wide demand concerns pose near-term risks. The stock presents a value opportunity given its low P/E of 13.6, though investors face volatility from competitive pressures and macroeconomic headwinds affecting IT spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
